Home / Health / First drug to slow Alzheimer’s disease approved

First drug to slow Alzheimer’s disease approved

The first drug claimed to help slow the progression of Alzheimer’s disease. It will be available to the NHS by 2022 if approved by regulators in the United States.

Biogen said its drug aducanumab would be the first treatment in “Reduces clinical decline” in patients in early stages of Alzheimer’s disease if given the green light next month.

This treatment offers new hope to patients in the early stages of the most common dementia. This affects about a million people living in the UK. This led to the death of EastEnders actress Dame Barbara Windsor in 2020.

A potentially innovative treatment It is the first drug to treat Alzheimer̵

7;s in nearly two decades. It cannot cure or reverse the disease. But hopefully it can slow down the rate of decline slightly.

The U.S. Food and Drug Administration (FDA) will decide whether to approve it for use on June 7.

If you get a green light The drug will be available in the UK by fall. and proposed to the NHS next year. daily mirror.

Biotechnology company Biogen Inc hopes that aducanumab will be approved for the treatment of Alzheimer’s in the United States.

(Dominick Reuters/AFP via Getty Images)

Dr Susan Kohlaas, director of research at Alzheimer’s Research UK, said the possible treatments “There is so much hope”

she told mirror: “It is very important that we begin to see disease-modifying treatments for dementia for the first time.

“This could be a very important step in changing the entire field of research.”

Dementia causes a progressive decline in brain function. which may affect memory Speed ​​of thinking, speech, emotion, and movement

Aducanumab, developed by Massachusetts-based Biogen. The goal is to help remove a harmful group of proteins called beta-amyloid from the brain.

Clinical studies were stopped last year after the drug appeared to be ineffective.

However, Biogen later said that preliminary analyzes of the results were “inaccurate” and that additional data sets indicated high doses of efficacy.

Additional reporting by the agency

Source link